Real-Time Monitoring in Continuous Manufacturing of Liposomal Nanoparticles

How do you ensure every nanoparticle is perfectly formed, without slowing down production?

In the pharmaceutical industry, the stakes are high when it comes to consistency, safety, and speed. Liposomal nanoparticles, key players in cancer therapies and mRNA vaccines, require demanding quality control. However, traditional batch processing struggles to meet these standards. That’s where continuous manufacturing and real-time analytics come in.

What to expect
In this application note, we showcase how a GMP-compliant continuous manufacturing system developed by the FDA and the University of Connecticut leverages the power of real-time monitoring. Using an integrated suite of process analytical technologies (PAT), including an Avantes UV-Vis spectrometer, the system achieves precise, inline control over critical parameters like drug encapsulation, particle size, and lipid concentration.

The spectrometer, coupled with predictive algorithms, enables high-sensitivity tracking of drug loading, right in the production flow. This eliminates delays, reduces waste, and ensures every batch meets therapeutic standards without costly downtime or off-spec rework.

The result? An advanced platform capable of scalable, end-to-end nanoparticle production—from buffer exchange to encapsulation—driven by real-time data and intelligent process control.

Explore the full story
Download the full application note to see how spectroscopy and continuous manufacturing are transforming the future of liposomal nanoparticle drug development.

Related Pages